Mizuho analyst Salim Syed raised the firm’s price target on Coherus Biosciences to $23 from $21 and keeps a Buy rating on the shares. The analyst added Eylea’s biosimilar to the model, with an expected launch in 2025, and is considering Udenyca’s autoinjector and on-body device launches in Q2 and 2023, respectively.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CHRS:
- Coherus Biosciences management to meet with Mizuho
- Coherus Biosciences price target lowered to $13 from $15 at Barclays
- Coherus Biosciences price target lowered to $26 from $30 at H.C. Wainwright
- Coherus Biosciences reports Q4 EPS (60c), consensus (84c)
- Coherus BioSciences Reports Fourth Quarter and Full Year 2022 Results
